Real-world evaluation of pembrolizumab monotherapy for PD-L1 positive (TPS>50%) metastatic NSCLC in France

被引：0

作者：

Perol, M. ^{[1
]}

Filleron, T. ^{[2
]}

Quantin, X. ^{[3
]}

Chouaid, C. ^{[4
]}

Valette, C. Audigier ^{[5
]}

Lena, H. ^{[6
]}

Kaderbhai, C. ^{[7
]}

Fabre, C. ^{[8
]}

Santorelli, M. ^{[9
]}

Bensimon, L. ^{[10
]}

Burke, T. ^{[11
]}

Couch, D. ^{[12
]}

Nguyen, E. ^{[12
]}

Courtinard, C. ^{[12
]}

机构：

[1] Ctr Leon Berard, Dept Med Oncol, Lyon, France

[2] Ctr Claudius Regaud, Biostat, Toulouse, France

[3] ICM Reg Canc Inst Montpellier, Montpellier, France

[4] CH Intercommunal Creteil, Creteil, France

[5] Hop St Musse, Toulon, France

[6] CHU Pontchaillou, Rennes, France

[7] Ctr Georges Francois Leclerc, Dijon, France

[8] IQVIA Co France, Capionis, Courbevoie, France

[9] Merck & Co Inc, Rahway, NJ USA

[10] MSD France, Dir Ass Evaluat Med Econ & Epidemiol, Puteaux La Defense, France

[11] Merck & Co Inc, Kenilworth, NJ USA

[12] UNICANCER, Data Off, Paris, France

来源：

JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

109P

引用

页码：S757 / S758

页数：2

共 50 条

[31] Real-World Prevalence of PD-L1 Expression in Chinese Patients with Advanced or Metastatic NSCLC: Express II Study [J].

Lin, D. ;

Yang, X. ;

Jiang, L. ;

Wang, W. ;

Hou, Y. ;

Li, Y. ;

Jin, Y. ;

Fan, X. ;

Sun, W. ;

Yun, J. ;

Li, P. ;

Kuang, D. ;

Zhang, L. ;

Ni, J. ;

Mao, A. ;

Tang, W. ;

Liu, Z. ;

Wang, J. ;

Xiao, S. .

JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) :S410-S410

[32] Phase 3 Trofuse-007 Study: Sacituzumab Tirumotecan Plus Pembrolizumab vs Pembrolizumab Alone for NSCLC with PD-L1 TPS ≥50% [J].

Frost, N. ;

Ghori, R. ;

Roy, A. ;

Nunes, A. T. ;

Yang, J. C. -H. .

JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) :S389-S390

[33] Post-progression outcomes of NSCLC patients with PD-L1 expression > 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study [J].

Cortellini, Alessio ;

Cannita, Katia ;

Tiseo, Marcello ;

Cortinovis, Diego L. ;

Aerts, Joachim G. J., V ;

Baldessari, Cinzia ;

Giusti, Raffaele ;

Ferrara, Miriam G. ;

D'Argento, Ettore ;

Grossi, Francesco ;

Guida, Annalisa ;

Berardi, Rossana ;

Morabito, Alessandro ;

Genova, Carlo ;

Antonuzzo, Lorenzo ;

Mazzoni, Francesca ;

De Toma, Alessandro ;

Signorelli, Diego ;

Gelibter, Alain ;

Targato, Giada ;

Rastelli, Francesca ;

Chiari, Rita ;

Rocco, Danilo ;

Gori, Stefania ;

De Tursi, Michele ;

Mansueto, Giovanni ;

Zoratto, Federica ;

Filetti, Marco ;

Bracarda, Sergio ;

Citarella, Fabrizio ;

Russano, Marco ;

Cantini, Luca ;

Nigro, Olga ;

Buti, Sebastiano ;

Minuti, Gabriele ;

Landi, Lorenza ;

Ricciardi, Serena ;

Migliorino, Maria R. ;

Natalizio, Salvatore ;

Simona, Carnio ;

De Filippis, Marco ;

Metro, Giulio ;

Adamo, Vincenzo ;

Russo, Alessandro ;

Spinelli, Gian P. ;

Di Maio, Massimo ;

Banna, Giuseppe L. ;

Friedlaender, Alex ;

Addeo, Alfredo ;

Pinato, David J. .

EUROPEAN JOURNAL OF CANCER, 2021, 148 :24-35

[34] Real-World Prognostic Model of Overall Survival in Patients With Advanced NSCLC Receiving Anti-PD1/PD-L1 as 2L Monotherapy [J].

Julian, C. ;

Machado, R. ;

Girish, S. ;

Chanu, P. ;

Heinzmann, D. ;

Harbron, C. ;

Gershon, A. ;

Pfeiffer, S. ;

Zou, W. ;

Quarmby, V. ;

Zhang, Q. ;

Chen, Y. .

JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) :S644-S644

[35] Comparative real-world analysis of pembrolizumab plus chemo vs platinum-doublet alone in metastatic non-squamous NSCLC with PD-L1 low [J].

Attili, I. ;

Valenza, C. ;

Santoro, C. ;

Antonarelli, G. ;

Aliaga, P. Trillo ;

Del Signore, E. ;

Catania, C. ;

Spitaleri, G. ;

Passaro, A. ;

de Marinis, F. .

ANNALS OF ONCOLOGY, 2022, 33 :S51-S51

[36] Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing [J].

Jones, Lauren ;

Rittberg, Rebekah ;

Leung, Bonnie ;

Shokoohi, Aria ;

Pender, Alexandra ;

Wong, Selina ;

Al-Hashami, Zamzam ;

Wang, Ying ;

Ho, Cheryl .

CURRENT ONCOLOGY, 2022, 29 (11) :8686-8692

[37] Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy [J].

Rittberg, Rebekah ;

Leung, Bonnie ;

Shokoohi, Aria ;

Pender, Alexandra ;

Wong, Selina ;

Al-Hashami, Zamzam ;

Wang, Ying ;

Ho, Cheryl .

CURRENT ONCOLOGY, 2023, 30 (06) :5299-5308

[38] Real-world adoption of PD-L1 testing in metastatic urothelial carcinoma. [J].

Gupta, Shilpa ;

Maculaitis, Martine C. ;

Bernstein, Andrew ;

Boudoures, Anna ;

Tesic-Schnell, Marija ;

Seal, Brian S. ;

Mulvihill, Emily ;

Doleh, Yunes .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

[39] First-line pembrolizumab monotherapy in metastatic PD-L1 positive non-small cell lung cancer: A real-world analysis of time on treatment in US community oncology practices [J].

Velcheti, V. ;

Chandwani, S. ;

Chen, X. ;

Pietanza, M. C. ;

Burke, T. .

ANNALS OF ONCOLOGY, 2018, 29 :18-18

[40] REAL WORLD OUTCOMES OF FIRST LINE PEMBROLIZUMAB MONOTHERAPY FOR ADVANCED PD-L1 POSITIVE NON-SMALL CELL LUNG CANCER [J].

Chu, R. ;

Vegas, A. ;

Gorry, C. ;

Power, D. .

VALUE IN HEALTH, 2022, 25 (01) :S253-S253

← 1 2 3 4 5 →

Real-world evaluation of pembrolizumab monotherapy for PD-L1 positive (TPS&gt;50%) metastatic NSCLC in France

Real-world evaluation of pembrolizumab monotherapy for PD-L1 positive (TPS>50%) metastatic NSCLC in France